Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
- The treatment involves a combination of multiple therapies, which may work together to enhance effectiveness.
- Patients will receive personalized care based on their individual health needs and responses to treatment.
- The study aims to assess the safety and effectiveness of this combination therapy in managing the disease.
- Participants will be closely monitored throughout the study to track their progress and any side effects.
- This approach is unique because it combines different treatment modalities, which may lead to better results compared to standard treatments.
- The study is designed to gather data that could help refine future treatment strategies for patients.
Third Opinion AI Generated Synopsis
Trial Summary
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
